Loading…

Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates

Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new mo...

Full description

Saved in:
Bibliographic Details
Published in:Chembiochem : a European journal of chemical biology 2019-11, Vol.20 (22), p.2876-2882
Main Authors: Renfrew, Anna K., Karges, Johannes, Scopelliti, Rosario, Bobbink, Felix D., Nowak‐Sliwinska, Patrycja, Gasser, Gilles, Dyson, Paul J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3
cites cdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3
container_end_page 2882
container_issue 22
container_start_page 2876
container_title Chembiochem : a European journal of chemical biology
container_volume 20
creator Renfrew, Anna K.
Karges, Johannes
Scopelliti, Rosario
Bobbink, Felix D.
Nowak‐Sliwinska, Patrycja
Gasser, Gilles
Dyson, Paul J.
description Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed. Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.
doi_str_mv 10.1002/cbic.201900236
format article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02140370v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232045513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</originalsourceid><addsrcrecordid>eNqF0U9P2zAYBnALbQLGduWIInEph3Z-bcdJjyGCgdRpCHVny7HfUKM06ewE1BsfAWnfkE8yV-06ictO_qPf-8jWQ8gp0AlQyr6aypkJozCNBy4PyDEIPh1nkvMPu71gLDsin0J4pJROJYdDcsQBKEtlfky-z7tn7W1IZu5h0b-9vBamd0-6R5vcD_0CWzcs315-Fx5bTEb3xd28iGi-XuFFcuc764eHpNStdTbOhM_kY62bgF926wn5eX01L2_Gsx_fbstiNjYiF3JsJVCwaIHVUIERmZCUV9IYkBprAIS80pkVEnmNFEzKMsksGmvqPKu15ifkYpu70I1aebfUfq067dRNMVObO8pAUJ7RJ4h2tLUr3_0aMPRq6YLBptEtdkNQjHFGRZoCj_T8HX3sBt_GnyjGIaVcsFxGNdkq47sQPNb7FwBVm1LUphS1LyUOnO1ih2qJds__thDBdAueXYPr_8Sp8vK2_Bf-B7yZmSI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2315034286</pqid></control><display><type>article</type><title>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</title><source>Wiley</source><creator>Renfrew, Anna K. ; Karges, Johannes ; Scopelliti, Rosario ; Bobbink, Felix D. ; Nowak‐Sliwinska, Patrycja ; Gasser, Gilles ; Dyson, Paul J.</creator><creatorcontrib>Renfrew, Anna K. ; Karges, Johannes ; Scopelliti, Rosario ; Bobbink, Felix D. ; Nowak‐Sliwinska, Patrycja ; Gasser, Gilles ; Dyson, Paul J.</creatorcontrib><description>Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed. Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.</description><identifier>ISSN: 1439-4227</identifier><identifier>EISSN: 1439-7633</identifier><identifier>DOI: 10.1002/cbic.201900236</identifier><identifier>PMID: 31102568</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic drugs ; Antitumor agents ; Benzene ; bioinorganic chemistry ; cancer ; Cervical cancer ; Cervical carcinoma ; Cervix ; Chemical Sciences ; Chemotherapy ; Coordination chemistry ; Coordination compounds ; Cymene ; Cytotoxicity ; Drug development ; Drug resistance ; Drugs ; Epithelium ; Exposure ; Ligands ; Medicinal Chemistry ; photoactivated chemotherapy (PACT) ; prodrugs ; Retina ; Retinal pigment epithelium ; Ruthenium ; Ruthenium compounds ; Side effects ; Toluene ; Toxicity</subject><ispartof>Chembiochem : a European journal of chemical biology, 2019-11, Vol.20 (22), p.2876-2882</ispartof><rights>2019 Wiley‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><rights>2019 Wiley-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</citedby><cites>FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</cites><orcidid>0000-0002-8299-0444 ; 0000-0002-4244-5097 ; 0000-0003-3117-3249 ; 0000-0001-5258-0260 ; 0000-0001-8161-8715</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31102568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02140370$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Renfrew, Anna K.</creatorcontrib><creatorcontrib>Karges, Johannes</creatorcontrib><creatorcontrib>Scopelliti, Rosario</creatorcontrib><creatorcontrib>Bobbink, Felix D.</creatorcontrib><creatorcontrib>Nowak‐Sliwinska, Patrycja</creatorcontrib><creatorcontrib>Gasser, Gilles</creatorcontrib><creatorcontrib>Dyson, Paul J.</creatorcontrib><title>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</title><title>Chembiochem : a European journal of chemical biology</title><addtitle>Chembiochem</addtitle><description>Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed. Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.</description><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Benzene</subject><subject>bioinorganic chemistry</subject><subject>cancer</subject><subject>Cervical cancer</subject><subject>Cervical carcinoma</subject><subject>Cervix</subject><subject>Chemical Sciences</subject><subject>Chemotherapy</subject><subject>Coordination chemistry</subject><subject>Coordination compounds</subject><subject>Cymene</subject><subject>Cytotoxicity</subject><subject>Drug development</subject><subject>Drug resistance</subject><subject>Drugs</subject><subject>Epithelium</subject><subject>Exposure</subject><subject>Ligands</subject><subject>Medicinal Chemistry</subject><subject>photoactivated chemotherapy (PACT)</subject><subject>prodrugs</subject><subject>Retina</subject><subject>Retinal pigment epithelium</subject><subject>Ruthenium</subject><subject>Ruthenium compounds</subject><subject>Side effects</subject><subject>Toluene</subject><subject>Toxicity</subject><issn>1439-4227</issn><issn>1439-7633</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqF0U9P2zAYBnALbQLGduWIInEph3Z-bcdJjyGCgdRpCHVny7HfUKM06ewE1BsfAWnfkE8yV-06ictO_qPf-8jWQ8gp0AlQyr6aypkJozCNBy4PyDEIPh1nkvMPu71gLDsin0J4pJROJYdDcsQBKEtlfky-z7tn7W1IZu5h0b-9vBamd0-6R5vcD_0CWzcs315-Fx5bTEb3xd28iGi-XuFFcuc764eHpNStdTbOhM_kY62bgF926wn5eX01L2_Gsx_fbstiNjYiF3JsJVCwaIHVUIERmZCUV9IYkBprAIS80pkVEnmNFEzKMsksGmvqPKu15ifkYpu70I1aebfUfq067dRNMVObO8pAUJ7RJ4h2tLUr3_0aMPRq6YLBptEtdkNQjHFGRZoCj_T8HX3sBt_GnyjGIaVcsFxGNdkq47sQPNb7FwBVm1LUphS1LyUOnO1ih2qJds__thDBdAueXYPr_8Sp8vK2_Bf-B7yZmSI</recordid><startdate>20191118</startdate><enddate>20191118</enddate><creator>Renfrew, Anna K.</creator><creator>Karges, Johannes</creator><creator>Scopelliti, Rosario</creator><creator>Bobbink, Felix D.</creator><creator>Nowak‐Sliwinska, Patrycja</creator><creator>Gasser, Gilles</creator><creator>Dyson, Paul J.</creator><general>Wiley Subscription Services, Inc</general><general>Wiley-VCH Verlag</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-8299-0444</orcidid><orcidid>https://orcid.org/0000-0002-4244-5097</orcidid><orcidid>https://orcid.org/0000-0003-3117-3249</orcidid><orcidid>https://orcid.org/0000-0001-5258-0260</orcidid><orcidid>https://orcid.org/0000-0001-8161-8715</orcidid></search><sort><creationdate>20191118</creationdate><title>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</title><author>Renfrew, Anna K. ; Karges, Johannes ; Scopelliti, Rosario ; Bobbink, Felix D. ; Nowak‐Sliwinska, Patrycja ; Gasser, Gilles ; Dyson, Paul J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Benzene</topic><topic>bioinorganic chemistry</topic><topic>cancer</topic><topic>Cervical cancer</topic><topic>Cervical carcinoma</topic><topic>Cervix</topic><topic>Chemical Sciences</topic><topic>Chemotherapy</topic><topic>Coordination chemistry</topic><topic>Coordination compounds</topic><topic>Cymene</topic><topic>Cytotoxicity</topic><topic>Drug development</topic><topic>Drug resistance</topic><topic>Drugs</topic><topic>Epithelium</topic><topic>Exposure</topic><topic>Ligands</topic><topic>Medicinal Chemistry</topic><topic>photoactivated chemotherapy (PACT)</topic><topic>prodrugs</topic><topic>Retina</topic><topic>Retinal pigment epithelium</topic><topic>Ruthenium</topic><topic>Ruthenium compounds</topic><topic>Side effects</topic><topic>Toluene</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Renfrew, Anna K.</creatorcontrib><creatorcontrib>Karges, Johannes</creatorcontrib><creatorcontrib>Scopelliti, Rosario</creatorcontrib><creatorcontrib>Bobbink, Felix D.</creatorcontrib><creatorcontrib>Nowak‐Sliwinska, Patrycja</creatorcontrib><creatorcontrib>Gasser, Gilles</creatorcontrib><creatorcontrib>Dyson, Paul J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Chembiochem : a European journal of chemical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Renfrew, Anna K.</au><au>Karges, Johannes</au><au>Scopelliti, Rosario</au><au>Bobbink, Felix D.</au><au>Nowak‐Sliwinska, Patrycja</au><au>Gasser, Gilles</au><au>Dyson, Paul J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</atitle><jtitle>Chembiochem : a European journal of chemical biology</jtitle><addtitle>Chembiochem</addtitle><date>2019-11-18</date><risdate>2019</risdate><volume>20</volume><issue>22</issue><spage>2876</spage><epage>2882</epage><pages>2876-2882</pages><issn>1439-4227</issn><eissn>1439-7633</eissn><abstract>Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed. Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31102568</pmid><doi>10.1002/cbic.201900236</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-8299-0444</orcidid><orcidid>https://orcid.org/0000-0002-4244-5097</orcidid><orcidid>https://orcid.org/0000-0003-3117-3249</orcidid><orcidid>https://orcid.org/0000-0001-5258-0260</orcidid><orcidid>https://orcid.org/0000-0001-8161-8715</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1439-4227
ispartof Chembiochem : a European journal of chemical biology, 2019-11, Vol.20 (22), p.2876-2882
issn 1439-4227
1439-7633
language eng
recordid cdi_hal_primary_oai_HAL_hal_02140370v1
source Wiley
subjects Antineoplastic drugs
Antitumor agents
Benzene
bioinorganic chemistry
cancer
Cervical cancer
Cervical carcinoma
Cervix
Chemical Sciences
Chemotherapy
Coordination chemistry
Coordination compounds
Cymene
Cytotoxicity
Drug development
Drug resistance
Drugs
Epithelium
Exposure
Ligands
Medicinal Chemistry
photoactivated chemotherapy (PACT)
prodrugs
Retina
Retinal pigment epithelium
Ruthenium
Ruthenium compounds
Side effects
Toluene
Toxicity
title Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A33%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Towards%20Light%E2%80%90Activated%20Ruthenium%E2%80%93Arene%20(RAPTA%E2%80%90Type)%20Prodrug%20Candidates&rft.jtitle=Chembiochem%20:%20a%20European%20journal%20of%20chemical%20biology&rft.au=Renfrew,%20Anna%20K.&rft.date=2019-11-18&rft.volume=20&rft.issue=22&rft.spage=2876&rft.epage=2882&rft.pages=2876-2882&rft.issn=1439-4227&rft.eissn=1439-7633&rft_id=info:doi/10.1002/cbic.201900236&rft_dat=%3Cproquest_hal_p%3E2232045513%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2315034286&rft_id=info:pmid/31102568&rfr_iscdi=true